COSMO Pharmaceuticals N.V. (COPN) Price & Analysis

Compare

3 Followers

COPN Stock Chart & Stats

Day’s Range― - ―

52-Week RangeCHF41.60 - CHF80.60

Previous CloseN/A

Volume25.75K

Average Volume (3M)21.31K

Market Cap

CHF958.07M

Enterprise ValueCHF1.00B

Total Cash (Recent Filing)CHF142.96M

Total Debt (Recent Filing)€2.20M

Price to Earnings (P/E)7.3

Beta1.01

Next Earnings

Jul 23, 2025

EPS EstimateN/A

Last Dividend Ex-Date

Jun 04, 2025

Dividend Yield2.91%

Share Statistics

EPS (TTM)7.91

Shares Outstanding17,543,522

10 Day Avg. Volume18,758

30 Day Avg. Volume21,313

Financial Highlights & Ratios

PEG Ratio-3.17

Price to Book (P/B)2.22

Price to Sales (P/S)0.00

P/FCF Ratio39.17

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price Target

CHF100.00

Price Target Upside75.75% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

COSMO Pharmaceuticals N.V. News

PremiumCompany Announcements

Cosmo Pharmaceuticals Sells ‘Digital Trust’ to Tinexta InfoCert

5d ago

PremiumCompany Announcements

Cosmo Pharmaceuticals Launches Pioneering Study Integrating AI with Apple Vision Pro

6d ago

PremiumCompany Announcements

Cosmo Pharmaceuticals’ 2025 General Meeting Approves Dividend Increase

1M ago

PremiumCompany Announcements

Cosmo Pharmaceuticals Advances AI and GI Drug Development at DDW 2025

2M ago

PremiumCompany Announcements

Cosmo Pharmaceuticals’ AI-Powered Cerebro Receives EU-MDR Certification

2M ago

PremiumCompany Announcements

Cosmo Pharmaceuticals Maintains 2025 Financial Forecast Amid CHMP Statement on Winlevi®

2M ago

PremiumCompany Announcements

Cosmo Pharmaceuticals to Appeal EMA’s Negative Opinion on Winlevi®

2M ago

PremiumCompany Announcements

Cosmo Pharmaceuticals Announces Agenda for 2025 General Meeting

2M ago

See All CH:COPN News

See All News >

Bulls Say, Bears Say

Bulls Say

Cash And Operational PerformanceEnding 2024 with €170.4M in cash and equivalents reflects solid operational performance.

Regulatory ApprovalsGI Genius poised for further advances with FDA clearance for latest-generation module 300 hardware.

Revenue GrowthPreliminary unaudited revenue demonstrates strength with a 186% year-over-year increase.

Bears Say

Asset Development UncertaintyBreezula is considered potentially the highest-value asset for Cosmo, with ongoing clinical development.

Dependence On ApprovalsMultiple additional catalysts expected, including potential approval for Winlevi in Europe.

Financials

Income Statement >

Options Prices

Currently, No data available

---

Ownership Overview

―

Insiders

2.54%

Mutual Funds

― Other Institutional Investors

94.30% Public Companies and

Individual Investors

Detailed Ownership Overview >

COPN FAQ

What was COSMO Pharmaceuticals N.V.’s price range in the past 12 months?

COSMO Pharmaceuticals N.V. lowest stock price was CHF41.60 and its highest was CHF80.60 in the past 12 months.

What is COSMO Pharmaceuticals N.V.’s market cap?

COSMO Pharmaceuticals N.V.’s market cap is CHF958.07M.

When is COSMO Pharmaceuticals N.V.’s upcoming earnings report date?

COSMO Pharmaceuticals N.V.’s upcoming earnings report date is Jul 23, 2025 which is in 24 days.

How were COSMO Pharmaceuticals N.V.’s earnings last quarter?

COSMO Pharmaceuticals N.V. released its earnings results on Mar 06, 2025. The company reported CHF3.374 earnings per share for the quarter, missing the consensus estimate of CHF3.616 by -CHF0.242.

Is COSMO Pharmaceuticals N.V. overvalued?

According to Wall Street analysts COSMO Pharmaceuticals N.V.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does COSMO Pharmaceuticals N.V. pay dividends?

COSMO Pharmaceuticals N.V. pays a Annually dividend of CHF1.65 which represents an annual dividend yield of 2.91%. See more information on COSMO Pharmaceuticals N.V. dividends here

What is COSMO Pharmaceuticals N.V.’s EPS estimate?

COSMO Pharmaceuticals N.V.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does COSMO Pharmaceuticals N.V. have?

COSMO Pharmaceuticals N.V. has 17,543,522 shares outstanding.

What happened to COSMO Pharmaceuticals N.V.’s price movement after its last earnings report?

COSMO Pharmaceuticals N.V. reported an EPS of CHF3.374 in its last earnings report, missing expectations of CHF3.616. Following the earnings report the stock price went down -12.923%.

Which hedge fund is a major shareholder of COSMO Pharmaceuticals N.V.?

Currently, no hedge funds are holding shares in CH:COPN

Company Description

COSMO Pharmaceuticals N.V.

COSMO Pharmaceuticals N.V. (COPN) is a specialty pharmaceutical company primarily focused on developing and commercializing products for the treatment of gastrointestinal diseases. The company leverages its proprietary clinical development and drug delivery technologies to create innovative therapies in areas such as inflammatory bowel disease (IBD), colon infections, and endoscopic procedures. COSMO Pharmaceuticals operates in the pharmaceuticals and biotechnology sectors, with a strong emphasis on R&D and a commitment to improving patient outcomes in the gastrointestinal field.

COPN Stock 12 Month Forecast

Average Price Target

CHF100.00

▲(75.75%Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"52":"CHF52","101":"CHF101","64.25":"CHF64.3","76.5":"CHF76.5","88.75":"CHF88.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF100.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":100,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF100.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[52,64.25,76.5,88.75,101],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jun<br/>2024","6":"Sep<br/>2024","9":"Jan<br/>2025","12":"Jun<br/>2025","25":"Jun<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.578,57.14892307692308,60.719846153846156,64.29076923076923,67.86169230769231,71.43261538461539,75.00353846153847,78.57446153846155,82.14538461538461,85.7163076923077,89.28723076923077,92.85815384615384,96.42907692307693,{"y":100,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.578,57.14892307692308,60.719846153846156,64.29076923076923,67.86169230769231,71.43261538461539,75.00353846153847,78.57446153846155,82.14538461538461,85.7163076923077,89.28723076923077,92.85815384615384,96.42907692307693,{"y":100,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,53.578,57.14892307692308,60.719846153846156,64.29076923076923,67.86169230769231,71.43261538461539,75.00353846153847,78.57446153846155,82.14538461538461,85.7163076923077,89.28723076923077,92.85815384615384,96.42907692307693,{"y":100,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":63.005,"date":1709251200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.949,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.888,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.479,"date":1717200000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":66.479,"date":1719792000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.017,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":77.133,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":72.307,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":65.742,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":61.494,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":63.425,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.675,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.578,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >